Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120456 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
A Phase 1 study, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 224
- Enrollment target
NCT02120456 is a Phase 1 study that has completed, run by LEO Pharma. The registered enrollment target is 224 participants.
The verdict
NCT02120456, a Phase 1 study, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 224 participants
- Enrollment target
Study Summary
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
Interventions
- DRUG Placebo
- DRUG LEO 43204
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120456
The ClinicalTrials.gov registry entry for NCT02120456 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02120456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120456 about?
NCT02120456 is a clinical study titled "Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis". Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive days compared to vehicle
What is the current status of trial NCT02120456?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2014-05. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02120456?
The interventions under investigation include: Placebo (DRUG), LEO 43204 (DRUG).
Who is sponsoring clinical trial NCT02120456?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.